Stock Price Prediction

DMAC stock has a bullish outlook with a price target of $7, representing a 21.1% upside from its current price of $5.78. This optimism is driven by HC Wainwright's "Strong Buy" rating and the company's solid cash position of $58.2M, which supports its clinical-stage developments. Institutional sentiment is also positive, with increased ownership and a low put/call ratio of 0.02, indicating confidence in the stock's future performance.

DMAC stock closed at $5.76 on January 31, 2025, down 1.54% during regular trading. Bearish sentiment arises from its negative earnings (-$1.08 EPS) and reliance on cash infusions like the recent $11.8M private placement, which highlights financial instability. Additionally, its limited revenue growth and high volatility make it unattractive for risk-averse investors.

The market consensus for DMAC's eps in the upcoming quarter is projected to be approximately $0.20 USD.